Partnering
Partnering Opportunities
Affibodys partnering strategy is to engage in partnerships centered around:
- Target-by-target development of novel biotherapeutics (discovery collaborations), or
- Out-licensing of Albumod™ technology
For opportunities for collaborative, partnership or licensing agreements, please contact bd@affibody.com.
Affibodys latest Press releases
2018-09-24
New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q2 (August 23, 2018)